MRNA
Moderna, Inc.
Stock
$190.01+1.07 (+0.57%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2B | $1.9B | $3.2B | $6.8B | $19.3B | $18.5B | $803M | $60M | $135M | $206M | $108M |
| Cost of revenue | $1.7B | $868M | $1.5B | $4.7B | $5.4B | $2.6B | $8.0M | $0 | $0 | — | — |
| Gross profit | $521M | $1.1B | $1.8B | $2.2B | $13.8B | $15.9B | $795M | $60M | $135M | — | — |
| R&D | $2.9B | $3.1B | $4.5B | $4.8B | $3.3B | $2.0B | $1.4B | $496M | $454M | $410M | $275M |
| Other operating expenses | $965M | $1.0B | $1.2B | $1.5B | $1.1B | $567M | $188M | $110M | $94M | — | — |
| Operating income | −$3.3B | −$3.1B | −$3.9B | −$4.2B | $9.4B | $13.3B | −$763M | −$546M | −$413M | −$269M | −$224M |
| Non-operating income | $233M | $306M | $338M | $297M | $155M | −$11M | $19M | $31M | $29M | $13M | $8.6M |
| Pretax income | −$3.1B | −$2.8B | −$3.6B | −$3.9B | $9.6B | $13.3B | −$744M | −$515M | −$384M | −$256M | −$215M |
| Taxes | $64M | $54M | −$46M | $772M | $1.2B | $1.1B | $3.0M | −$1.0M | $326K | −$80K | $1.0M |
| Net income | −$3.2B | −$2.8B | −$3.6B | −$4.7B | $8.4B | $12.2B | −$747M | −$514M | −$385M | −$256M | −$216M |
| Diluted EPS | −$7.99 | −$7.26 | −$9.28 | −$12.33 | $20.12 | $28.29 | −$1.96 | −$1.55 | −$4.95 | −$4.18 | −$3.79 |
| Diluted shares | — | 389.0M | 384.0M | 382.0M | 416.0M | 431.0M | 381.0M | 331.0M | 81.1M | 64.5M | 60.7M |
| Revenue growth | — | −39.9% | −52.7% | −64.4% | +4.3% | +2,200.2% | +1,238.3% | −55.6% | −34.4% | +89.9% | — |
| Gross margin | 23.4% | 55.3% | 54.8% | 31.5% | 71.9% | 85.8% | 99.0% | 100.0% | 100.0% | — | — |
| Operating margin | −149.0% | −158.1% | −121.9% | −61.9% | 48.9% | 72.0% | −95.0% | −910.0% | −306.0% | −130.9% | −206.4% |
| Net margin | −141.4% | −145.2% | −110.0% | −68.8% | 43.4% | 66.1% | −93.0% | −856.7% | −284.8% | −124.3% | −199.5% |